Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric S Rovner

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Advances in Therapy|June 22, 2019
Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)Kevin V Carlson, Eric S Rovner, Kavita V Nair, et al.
Lower Urinary Tract Symptoms|May 14, 2021
Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry studyKevin V Carlson, Eric S Rovner, Kavita V Nair, et al.
BJU International|August 17, 2010
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndromePeter K Sand, Theodore M Johnson Ii, Eric S Rovner, et al.
American Journal of Obstetrics and Gynecology|January 27, 2005
A new questionnaire for urinary incontinence diagnosis in women: development and testingCatherine S Bradley, Eric S Rovner, Mark A Morgan, et al.
The Journal of Urology|September 22, 2018
Six-Month Results of Selective Bladder Denervation in Women with Refractory Overactive BladderStefan De Wachter, Kevin D Benson, Roger R Dmochowski, et al.
BMC Urology|April 2, 2025
Satisfaction and persistence with vibegron in the first 6 months of overactive bladder treatment: interim results of the phase 4, real-world COMPOSUR studyRoger R Dmochowski, Eric S Rovner, Michael J Kennelly, et al.
The Journal of Urology|November 13, 2004
Is urine methylhistamine a useful marker for interstitial cystitis?Deborah R Erickson, Allen R Kunselman, Christina M Bentley, et al.
BJU International|November 17, 2009
Patient-reported reasons for discontinuing overactive bladder medicationJoshua S Benner, Michael B Nichol, Eric S Rovner, et al.
The Journal of Urology|January 16, 2007
Changes in urine markers and symptoms after bladder distention for interstitial cystitisDeborah R Erickson, Allen R Kunselman, Christina M Bentley, et al.
BMC Urology|April 24, 2023
Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladderRoger R Dmochowski, Eric S Rovner, Michael J Kennelly, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Advances in Therapy|June 22, 2019
Factors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSPECTIVE)Kevin V Carlson, Eric S Rovner, Kavita V Nair, et al.
Lower Urinary Tract Symptoms|May 14, 2021
Persistence with mirabegron or antimuscarinic treatment for overactive bladder syndrome: Findings from the PERSPECTIVE registry studyKevin V Carlson, Eric S Rovner, Kavita V Nair, et al.
BJU International|August 17, 2010
Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndromePeter K Sand, Theodore M Johnson Ii, Eric S Rovner, et al.
American Journal of Obstetrics and Gynecology|January 27, 2005
A new questionnaire for urinary incontinence diagnosis in women: development and testingCatherine S Bradley, Eric S Rovner, Mark A Morgan, et al.
The Journal of Urology|September 22, 2018
Six-Month Results of Selective Bladder Denervation in Women with Refractory Overactive BladderStefan De Wachter, Kevin D Benson, Roger R Dmochowski, et al.
BMC Urology|April 2, 2025
Satisfaction and persistence with vibegron in the first 6 months of overactive bladder treatment: interim results of the phase 4, real-world COMPOSUR studyRoger R Dmochowski, Eric S Rovner, Michael J Kennelly, et al.
The Journal of Urology|November 13, 2004
Is urine methylhistamine a useful marker for interstitial cystitis?Deborah R Erickson, Allen R Kunselman, Christina M Bentley, et al.
BJU International|November 17, 2009
Patient-reported reasons for discontinuing overactive bladder medicationJoshua S Benner, Michael B Nichol, Eric S Rovner, et al.
The Journal of Urology|January 16, 2007
Changes in urine markers and symptoms after bladder distention for interstitial cystitisDeborah R Erickson, Allen R Kunselman, Christina M Bentley, et al.
BMC Urology|April 24, 2023
Study design of a phase 4, real-world study (COMPOSUR) to evaluate vibegron in patients with overactive bladderRoger R Dmochowski, Eric S Rovner, Michael J Kennelly, et al.
Pageof 11